Formosa Pharmaceuticals and AimMax Therapeutics announce NDA Submission to USFDA for APP13007
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
Subscribe To Our Newsletter & Stay Updated